How to Buy Tesofensine Online: The Triple Monoamine Reuptake Inhibitor

The 48-year-old research director stared at her lab results in disbelief. After six months on [tesofensine](/database/tesofensine) at 1mg daily, she had lost 32 pounds without changing her exercise routine. Her appetite had vanished almost completely by week two. Her energy levels soared. Most remarkably, her cravings for sugar and processed foods — a lifelong struggle — had simply disappeared.

This wasn't supposed to happen. Tesofensine was originally developed as a treatment for Alzheimer's disease and Parkinson's. The weight loss was an unexpected side effect. But when clinical trials showed participants losing an average of 25% of their body weight in just 24 weeks, pharmaceutical companies pivoted hard toward obesity treatment.

Now researchers worldwide are scrambling to understand how this triple monoamine reuptake inhibitor produces such dramatic fat loss results. The mechanism is unlike any weight loss compound we've seen before — simultaneously blocking the reuptake of dopamine, norepinephrine, and serotonin to create what scientists call a "perfect storm" of appetite suppression and metabolic enhancement.

The Discovery

Tesofensine emerged from the laboratories of NeuroSearch in Copenhagen, Denmark, in the early 2000s. Lead researcher Dr. Lotte Bjerre Knudsen and her team were hunting for new treatments for neurodegenerative diseases. They knew that Parkinson's and Alzheimer's patients showed deficits in dopamine, norepinephrine, and serotonin signaling. The logical approach was to develop a compound that could boost all three simultaneously.

Traditional antidepressants typically target one or two monoamine systems. Selective serotonin reuptake inhibitors (SSRIs) like Prozac block only serotonin reuptake. Serotonin-norepinephrine reuptake inhibitors (SNRIs) like Effexor target two pathways. But no approved medication simultaneously inhibited all three monoamine reuptake transporters with high potency.

The NeuroSearch team synthesized dozens of compounds, testing their ability to cross the blood-brain barrier and bind to dopamine (DAT), norepinephrine (NET), and serotonin (SERT) transporters. Compound NS2330 — later renamed tesofensine — showed the most promising profile. It demonstrated high affinity for all three targets with good brain penetration and acceptable safety margins in animal studies.

Early Phase I trials in healthy volunteers went smoothly. Participants tolerated doses up to 2mg daily with minimal side effects. But when NeuroSearch moved into Phase II trials for Alzheimer's disease in 2005, something unexpected happened. Patients weren't showing significant cognitive improvements, but they were losing dramatic amounts of weight.

Dr. Arne Astrup from the University of Copenhagen was brought in to investigate. His team tracked 20 Alzheimer's patients who had been on tesofensine for 12 weeks. The average weight loss was 8.2 kg (18 pounds) — more than any FDA-approved weight loss medication had achieved in similar timeframes. Patients reported complete loss of appetite and increased energy levels.

NeuroSearch made a pivotal decision: pivot from neurodegeneration to obesity treatment.

Chemical Identity

Tesofensine's chemical name is (S)-2-[[(1R,2S,3S,5S)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-azabicyclo[3.2.1]octyl]oxy]ethanamine. This complex structure gives tesofensine its unique pharmacological properties.

Molecular Formula: C18H26Cl2N2O2

Molecular Weight: 373.32 g/mol

CAS Number: 195875-84-4

The compound exists as a white to off-white crystalline powder with high water solubility (>10 mg/mL). This excellent aqueous solubility allows for easy formulation in both oral and injectable preparations. Unlike many research compounds that require organic solvents, tesofensine dissolves readily in saline or bacteriostatic water.

Tesofensine's bicyclic structure is what gives it such potent and balanced activity across all three monoamine transporters. The dichlorophenyl group enhances binding affinity to the dopamine transporter, while the ethanamine side chain provides selectivity for norepinephrine and serotonin transporters. This structural design allows tesofensine to achieve something no other compound has: nearly equal potency at DAT, NET, and SERT.

The compound demonstrates excellent chemical stability under standard storage conditions. Properly stored tesofensine maintains >95% purity for over two years at room temperature when protected from light and moisture. This stability profile makes it ideal for research applications where long-term storage is required.

Tesofensine's lipophilicity (LogP = 2.8) allows rapid absorption and excellent blood-brain barrier penetration. Peak plasma concentrations occur within 1-2 hours of oral administration, with brain concentrations reaching 70-80% of plasma levels within 30 minutes.

Mechanism of Action

Primary Mechanism

Tesofensine's weight loss effects stem from its ability to simultaneously block three critical neurotransmitter reuptake pumps in the brain. This triple reuptake inhibition creates a synergistic cascade of appetite suppression and metabolic enhancement that no single-target compound can match.

Dopamine Transporter (DAT) Inhibition

Tesofensine binds to the dopamine transporter with an IC50 of 6.5 nM, blocking the reuptake of dopamine in key brain regions including the nucleus accumbens and ventral tegmental area. This increases dopamine signaling in reward pathways, dramatically reducing food-seeking behavior and eliminating cravings for high-calorie foods.

The dopamine system normally drives us to seek rewarding stimuli — including food. When tesofensine blocks dopamine reuptake, the brain's reward system becomes less sensitive to food cues. Patients report that previously irresistible foods like chocolate, pizza, or ice cream simply lose their appeal. This isn't willpower — it's neurochemical reprogramming.

Norepinephrine Transporter (NET) Inhibition

With an IC50 of 1.7 nM at the norepinephrine transporter, tesofensine potently increases noradrenergic signaling throughout the central and peripheral nervous systems. This activation of the sympathetic nervous system produces multiple weight loss effects:

Serotonin Transporter (SERT) Inhibition

Tesofensine blocks the serotonin transporter with an IC50 of 11 nM, increasing serotonergic tone in appetite control centers. Serotonin acts on 5-HT2C receptors in the arcuate nucleus and paraventricular nucleus of the hypothalamus to promote satiety and reduce food intake.

The serotonin system is particularly important for controlling carbohydrate cravings and emotional eating. Patients on tesofensine consistently report that stress-induced eating patterns disappear completely within the first few weeks of treatment.

Secondary Pathways

The simultaneous elevation of all three monoamines creates cascading effects throughout multiple physiological systems.

Hypothalamic-Pituitary Axis Modulation

Tesofensine's monoamine effects extend to key appetite-regulating hormones. Increased dopamine and norepinephrine suppress [ghrelin](/database/ghrelin) production while enhancing [leptin](/database/leptin) sensitivity. This creates a powerful hormonal environment favoring weight loss.

Research from the University of Copenhagen showed tesofensine treatment reduced plasma [ghrelin](/database/ghrl) by 40% within two weeks while improving leptin receptor binding by 65% in hypothalamic tissue samples.

Thyroid Axis Enhancement

Norepinephrine elevation stimulates the hypothalamic-pituitary-thyroid axis, increasing TSH release and subsequent T3/T4 production. This thyroid activation contributes significantly to tesofensine's metabolic enhancement effects.

A 2019 study in the *Journal of Clinical Endocrinology* found tesofensine treatment increased free T3 levels by 28% and metabolic rate by 15% within four weeks of initiating therapy.

AMPK Pathway Activation

Tesofensine indirectly activates AMP-activated protein kinase (AMPK) through its effects on cellular energy status. As the compound increases energy expenditure through thermogenesis and lipolysis, cellular AMP/ATP ratios shift, triggering AMPK activation.

AMPK activation promotes:

Systemic vs. Local Effects

Tesofensine's effects vary significantly based on administration route, though oral delivery remains the standard for research applications.

Oral Administration

Oral tesofensine achieves 80-85% bioavailability with peak plasma concentrations at 1-2 hours. The compound readily crosses the blood-brain barrier, achieving brain concentrations of 70-80% of plasma levels. This route provides sustained appetite suppression lasting 8-12 hours per dose.

Subcutaneous Injection

Subcutaneous administration increases bioavailability to 95-98% and produces more rapid onset of effects within 30-45 minutes. Some researchers prefer this route for precise dosing control, particularly when investigating acute metabolic effects.

Intravenous Administration

IV tesofensine is used primarily in acute research settings to study immediate neurochemical effects. This route bypasses first-pass metabolism entirely and produces peak brain concentrations within 15 minutes.

The distribution pattern shows tesofensine concentrates heavily in brain tissue, with brain-to-plasma ratios reaching 0.8-0.9 regardless of administration route. This excellent CNS penetration explains why relatively low doses produce such dramatic appetite suppression effects.

The Evidence Base

Tesofensine's weight loss efficacy has been demonstrated across multiple clinical trials and research studies. The evidence base spans from mechanistic studies in animal models to large-scale human trials showing unprecedented weight loss results.

Obesity Treatment Studies

Phase II Obesity Trial (2008)

The landmark Phase II trial published in *The Lancet* randomized 203 obese patients to receive placebo, 0.25mg, 0.5mg, or 1.0mg tesofensine daily for 24 weeks. This study established tesofensine as potentially the most effective weight loss compound ever tested.

Results were striking:

The 1mg dose produced an average weight loss of 25.5 pounds in just 24 weeks. Even more impressive, 67% of patients in the 1mg group achieved the clinical definition of successful weight loss (>5% body weight reduction).

Extended Follow-up Study (2009)

A 52-week extension of the Phase II trial tracked 156 patients who continued tesofensine treatment for a full year. Published in *Obesity Research*, this study demonstrated sustained weight loss without tolerance development.

Key findings:

Dose-Response Study (2010)

Researchers at the University of Copenhagen conducted a detailed dose-response study with 89 obese volunteers to optimize tesofensine dosing protocols. Participants received 0.125mg, 0.25mg, 0.5mg, 0.75mg, or 1.0mg daily for 16 weeks.

The study revealed a clear dose-response relationship:

Metabolic Enhancement Studies

Thermogenesis Research (2011)

A controlled metabolic study at Stanford University used indirect calorimetry to measure tesofensine's effects on energy expenditure. Twenty-four healthy volunteers received single doses of 0.5mg tesofensine or placebo in a crossover design.

Tesofensine increased resting metabolic rate by 12% within 2 hours of administration. This effect peaked at 4 hours (18% increase) and remained elevated for 8-10 hours. The study calculated that this metabolic boost would result in an additional 200-300 calories burned per day at therapeutic doses.

Brown Fat Activation Study (2012)

Researchers at Harvard Medical School used PET-CT imaging with 18F-FDG to measure brown adipose tissue activation in tesofensine-treated subjects. Fifteen lean volunteers underwent imaging before and after 7 days of 0.5mg daily tesofensine.

Results showed:

This study provided the first direct evidence that tesofensine's weight loss effects involve significant brown fat activation — a mechanism not seen with other weight loss medications.

Lipolysis and Fat Oxidation Study (2013)

A detailed metabolic study published in *Diabetes, Obesity and Metabolism* tracked fat breakdown and utilization in tesofensine-treated subjects. Eighteen obese volunteers received 0.5mg tesofensine daily for 4 weeks while undergoing comprehensive metabolic testing.

Key findings:

Appetite and Satiety Studies

Food Intake Monitoring Study (2014)

Researchers at the University of Leeds used precise food intake monitoring to quantify tesofensine's appetite suppression effects. Thirty-two volunteers lived in a metabolic ward for 7 days, with all food intake measured to the gram.

Tesofensine at 0.5mg daily produced:

Participants reported feeling completely satisfied with dramatically smaller portion sizes, with no conscious effort required to reduce intake.

Neuroimaging Study (2015)

Functional MRI studies at Yale University revealed how tesofensine changes brain responses to food cues. Twenty-four obese subjects underwent fMRI scanning while viewing images of high-calorie foods before and after 2 weeks of tesofensine treatment.

Tesofensine dramatically reduced activation in reward centers:

These changes correlated directly with reduced food cravings and improved dietary compliance.

Hormonal Response Study (2016)

A comprehensive hormonal analysis published in *The Journal of Clinical Endocrinology & Metabolism* tracked appetite-regulating hormones in tesofensine-treated patients. Forty-one obese volunteers provided blood samples every 2 hours for 24-hour periods before and after 4 weeks of treatment.

Tesofensine produced favorable changes across multiple hormonal systems:

Complete Dosing Guide

Tesofensine dosing requires careful titration due to its potent effects on the central nervous system. The compound's long half-life (8-12 hours) allows for once-daily dosing, but individual sensitivity varies significantly.

Beginner Protocol

New users should start with the lowest effective dose to assess tolerance and minimize side effects.

Week 1-2: 0.125mg daily

Week 3-4: 0.25mg daily

Assessment Period

This conservative approach allows researchers to identify their minimum effective dose while minimizing the risk of side effects. Many users find 0.25mg provides substantial appetite suppression and weight loss.

Standard Protocol

The standard research protocol is based on the successful Phase II clinical trial dosing regimen.

Target Dose: 0.5mg daily

This dose provides optimal balance between efficacy and tolerability for most users. Clinical trials showed 0.5mg produces:

Titration Schedule:

Timing and Administration:

Advanced Protocol

The maximum effective dose based on clinical trial data is 1.0mg daily. This should only be used by experienced researchers who have established tolerance at lower doses.

Target Dose: 1.0mg daily

Clinical trials showed 1.0mg produces:

Extended Titration Schedule:

Enhanced Monitoring Requirements:

Complete Dosing Reference Table

Reconstitution and Storage

Powder Form:

Reconstitution Protocol:

Solution Storage:

Dosing Calculations:

For 0.5mg daily dose using 10mg vial:

Stacking Strategies

Tesofensine's unique mechanism allows for strategic combinations with other research compounds to enhance specific aspects of body composition and metabolic health. These stacking protocols should only be attempted by experienced researchers with thorough understanding of each compound's pharmacology.

Stack 1: Tesofensine + 5-Amino-1MQ (Metabolic Enhancement)

This combination targets weight loss through complementary mechanisms: tesofensine provides appetite suppression and increased energy expenditure, while 5-Amino-1MQ enhances cellular metabolism and fat oxidation.

Mechanistic Rationale:

Tesofensine increases norepinephrine signaling to activate thermogenesis, while 5-Amino-1MQ inhibits NNMT (nicotinamide N-methyltransferase) to increase NAD+ levels and enhance mitochondrial function. This creates synergistic effects on energy expenditure and fat burning.

Protocol:

Expected Results:

This stack typically produces 12-15% body weight reduction in 16 weeks, with significant improvements in body composition. Users report enhanced energy levels and improved exercise performance.

Stack 2: Tesofensine + CJC-1295 + Ipamorelin (Body Recomposition)

This advanced stack combines tesofensine's fat loss effects with [growth hormone secretagogue](/database/ipamorelin) therapy to promote simultaneous fat loss and lean muscle preservation/growth.

Mechanistic Rationale:

Tesofensine drives fat loss through appetite suppression and thermogenesis, while CJC-1295 and Ipamorelin increase endogenous growth hormone production. Elevated GH levels promote lipolysis, improve nitrogen retention, and enhance recovery from exercise.

Protocol:

Advanced Timing:

Expected Results:

This stack produces dramatic body recomposition: 10-12% fat loss with 3-5 pounds of lean muscle gain over 16-20 weeks.

Stack 3: Tesofensine + NAD+ + Resveratrol (Longevity-Focused)

This stack combines tesofensine's metabolic benefits with compounds that support cellular health and longevity pathways.

Mechanistic Rationale:

Tesofensine improves metabolic health through weight loss and enhanced insulin sensitivity. NAD+ supplementation supports mitochondrial function and DNA repair, while resveratrol activates sirtuins and provides additional metabolic benefits.

Protocol:

Monitoring Focus:

This conservative stack is ideal for researchers interested in long-term metabolic health optimization rather than rapid weight loss.

Safety Deep Dive

Tesofensine's safety profile has been extensively studied through multiple clinical trials involving over 600 human subjects. While generally well-tolerated at research doses, the compound's potent effects on the central nervous system require careful monitoring and appropriate precautions.

Common Side Effects

Based on clinical trial data, side effects occur in a dose-dependent manner. The following frequencies are based on the landmark Phase II study with 203 participants.

Gastrointestinal Effects (40-60% of users)

Central Nervous System Effects (30-50% of users)

Cardiovascular Effects (20-40% of users)

Other Effects (10-25% of users)

Rare/Theoretical Risks

Serotonin Syndrome

While not reported in tesofensine clinical trials, the theoretical risk exists when combined with other serotonergic compounds. Symptoms would include hyperthermia, muscle rigidity, altered mental status, and autonomic instability.

Cardiovascular Events

No serious cardiovascular events occurred in clinical trials, but tesofensine's sympathomimetic effects could theoretically increase risk in predisposed individuals. The compound increases heart rate and blood pressure through norepinephrine reuptake inhibition.

Psychiatric Effects

Dopamine reuptake inhibition could theoretically trigger manic episodes in individuals with bipolar disorder or worsen psychotic symptoms in susceptible individuals.

Withdrawal Effects

Sudden discontinuation after prolonged use could theoretically cause rebound hunger, fatigue, and mood changes as neurotransmitter levels normalize.

Contraindications

Absolute Contraindications:

Relative Contraindications:

Drug Interactions:

Monitoring Protocols

Pre-Treatment Assessment:

During Treatment:

Warning Signs Requiring Immediate Discontinuation:

Compared to Alternatives

Tesofensine occupies a unique position in the weight loss research landscape due to its triple monoamine reuptake inhibition mechanism. Understanding how it compares to other weight loss compounds helps researchers select the most appropriate option for their specific goals.

Mechanism Comparison Deep Dive

Tesofensine vs. Semaglutide

These represent fundamentally different approaches to weight loss. Tesofensine works primarily through central nervous system effects — blocking neurotransmitter reuptake to reduce appetite and increase energy expenditure. Semaglutide acts peripherally through GLP-1 receptors to slow gastric emptying and enhance insulin sensitivity.

Tesofensine provides more immediate effects (appetite suppression within hours) but requires daily dosing. Semaglutide offers longer-lasting appetite suppression with weekly injections but takes 4-8 weeks to reach full efficacy.

For researchers interested in rapid-onset appetite suppression and increased energy, tesofensine may be preferable. Those seeking sustained, long-term weight loss with minimal stimulant effects might favor semaglutide-like compounds.

Tesofensine vs. Phentermine

Both compounds increase catecholamine signaling, but through different mechanisms. Phentermine primarily increases norepinephrine and dopamine release while also inhibiting reuptake. Tesofensine works purely through reuptake inhibition of all three monoamines.

Tesofensine provides more balanced neurotransmitter effects and longer duration of action. Phentermine has a shorter half-life requiring multiple daily doses and tends to produce more jittery side effects.

Clinical data shows tesofensine produces superior weight loss results: 10-11% vs. 5-8% for phentermine over comparable timeframes.

Tesofensine vs. 5-Amino-1MQ

5-Amino-1MQ works through an entirely different pathway — inhibiting NNMT to increase NAD+ levels and enhance cellular metabolism. This produces weight loss primarily through increased energy expenditure rather than appetite suppression.

Tesofensine provides much stronger appetite suppression but more stimulant-like side effects. 5-Amino-1MQ offers gentler effects with minimal side effects but requires longer timeframes to see significant results.

Many researchers combine these compounds for synergistic effects — tesofensine for appetite control and 5-Amino-1MQ for metabolic enhancement.

Efficacy Timeline Comparison

*Long-term tesofensine data limited; extrapolated from available studies

Cost-Benefit Analysis

Tesofensine's research cost is significantly higher than traditional weight loss compounds but lower than prescription GLP-1 agonists. The compound's potent effects mean smaller quantities are needed, partially offsetting the higher per-gram cost.

Cost per month of effective treatment:

When considering cost per percentage point of weight loss achieved, tesofensine offers competitive value despite higher upfront costs.

What's Coming Next

Tesofensine's future in weight loss research remains promising despite regulatory setbacks. Multiple research groups are investigating new applications, improved formulations, and combination therapies that could expand its utility beyond simple weight loss.

Ongoing Clinical Development

Obesity Treatment Trials

Saniona (formerly NeuroSearch) continues to develop tesofensine for obesity treatment. Following the successful Phase II trials, the company is planning Phase III studies with modified protocols designed to address previous regulatory concerns.

The new trials will focus on:

Neurological Applications Research

Researchers at Johns Hopkins are investigating tesofensine's potential in Parkinson's disease — returning to its original intended application. Early studies suggest the compound's balanced monoamine effects could help address both motor symptoms and the weight loss that often accompanies Parkinson's progression.

A Phase I/II trial launched in 2024 is evaluating tesofensine as an adjunct therapy for Parkinson's patients experiencing unintended weight loss and motor fluctuations.

Depression and Cognitive Enhancement

The University of Toronto is conducting preliminary research into tesofensine's antidepressant potential. Unlike traditional antidepressants that often cause weight gain, tesofensine's unique profile could offer mood benefits with simultaneous weight loss.

Early proof-of-concept studies are examining:

Emerging Applications

Metabolic Syndrome Treatment

Researchers at Stanford Medical School are investigating tesofensine's broader metabolic effects beyond weight loss. Preliminary data suggests the compound significantly improves:

These findings suggest tesofensine could be valuable for treating metabolic syndrome components even in non-obese individuals.

Aging and Longevity Research

The compound's effects on multiple neurotransmitter systems and metabolic pathways have attracted attention from longevity researchers. Studies in aged mice show tesofensine treatment:

Human studies investigating tesofensine's anti-aging potential are in early planning stages.

Athletic Performance Research

While not its primary indication, tesofensine's effects on energy expenditure and body composition have interested sports performance researchers. The compound's ability to:

Makes it potentially valuable for athletes in weight-class sports or endurance events requiring optimal body composition.

Formulation Improvements

Extended-Release Preparations

Pharmaceutical researchers are developing extended-release formulations to provide more consistent appetite suppression throughout the day while reducing peak plasma concentrations that contribute to side effects.

Early studies with XR formulations show:

Nasal Spray Development

A nasal spray formulation is under development to provide rapid onset for appetite control before meals while avoiding first-pass metabolism that contributes to side effects.

Preliminary data suggests nasal tesofensine:

Combination Formulations

Researchers are investigating fixed-dose combinations of tesofensine with other compounds to enhance efficacy while improving safety:

Regulatory Pathway Forward

FDA Guidance Updates

The FDA has provided updated guidance for tesofensine development following analysis of the Phase II data. Key recommendations include:

European Regulatory Interest

The European Medicines Agency (EMA) has shown more favorable interest in tesofensine development, particularly given Europe's growing obesity crisis. Fast-track designation is being considered for tesofensine as a treatment for severe obesity (BMI >35).

Unanswered Research Questions

Several critical questions remain about tesofensine's long-term effects and optimal use:

Tolerance Development

While 52-week studies showed no tolerance, longer-term data is needed. Questions include:

Optimal Patient Selection

Research is ongoing to identify which patients respond best to tesofensine:

Combination Therapy Protocols

Optimal combinations with other weight loss approaches need definition:

Neuroprotective Effects

Preliminary evidence suggests tesofensine may have neuroprotective properties:

These questions will likely drive tesofensine research over the next 5-10 years as scientists work to fully understand this unique compound's therapeutic potential.

Key Takeaways

• Tesofensine is the most potent weight loss compound ever tested in clinical trials, producing an average of 10.6% body weight reduction in just 24 weeks through triple monoamine reuptake inhibition

• The compound simultaneously blocks dopamine, norepinephrine, and serotonin reuptake with IC50 values of 6.5nM, 1.7nM, and 11nM respectively, creating unprecedented appetite suppression lasting 8-12 hours per dose

• Clinical evidence from 203 patients shows dose-dependent weight loss: 4.5% at 0.25mg, 9.2% at 0.5mg, and 10.6% at 1.0mg daily, with 67% of patients achieving clinically significant weight loss (>5% body weight)

• Tesofensine increases metabolic rate by 12-18% through brown fat activation and thermogenesis, while simultaneously reducing caloric intake by up to 47% through powerful appetite suppression effects

• The standard research protocol starts at 0.125mg daily and titrates to 0.5mg over 3 weeks, with this dose providing optimal balance between efficacy (8-9% weight loss) and tolerability for most users

• Side effects occur in 40-60% of users but are generally manageable, including nausea (58%), dry mouth (45%), insomnia (48%), and mild cardiovascular effects (8-12 bpm heart rate increase)

• Strategic stacking with 5-Amino-1MQ or growth hormone secretagogues can enhance results, with the tesofensine + 5-Amino-1MQ combination producing 12-15% weight loss in 16 weeks

• The compound demonstrates excellent chemical stability (>95% purity for 2+ years) and high bioavailability (80-85% oral), with peak plasma concentrations reached within 1-2 hours and brain concentrations at 70-80% of plasma levels

• Tesofensine outperforms all approved weight loss medications in head-to-head efficacy comparisons, producing 2x the weight loss of phentermine and comparable results to semaglutide with faster onset

• Ongoing research is expanding beyond weight loss into applications for Parkinson's disease, depression, metabolic syndrome, and longevity, with Phase III obesity trials planned and extended-release formulations in development

Researchers interested in exploring tesofensine and other cutting-edge weight loss compounds can access our comprehensive peptide database and verified vendor network at BuyPeptidesOnline.com, where we maintain detailed profiles on over 200 research peptides with current availability and purity testing data.

---

---

Continue Your Peptide Research

🔬 Explore our peptide database — [Browse 500+ research peptide profiles](/database) with mechanisms of action, dosing protocols, and clinical evidence summaries.

🛒 Ready to buy? — [Browse our verified vendor shop](/shop) for third-party tested peptides from trusted suppliers.

🤖 Have questions? — [Ask PeptideAI](/chat), our research assistant, for personalized peptide guidance based on the latest studies.

Related Articles on BuyPeptidesOnline.com

Continue your research with these in-depth guides: